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RESEARCH COMMUNICATION
The p400 E1A-associated
protein is a novel component
of the p53 → p21
senescence pathway
Ho Man Chan,1 Masako Narita,2 Scott W. Lowe,2
and David M. Livingston1,3
1Dana-Farber Cancer Institute, Harvard Medical School,
Boston Massachusetts 02115, USA; 2Cold Spring Harbor
Laboratory, Cold Spring Harbor, New York 11724, USA
Adenovirus E1A-associated p400 belongs to the SWI2/
SNF2 family of chromatin remodeling proteins. Here,
we report that p400 is a component of the p53–
p21WAF1/CIP1/sid1 pathway, regulating the p21 tran-
scription and senescence induction program. Acute
depletion of p400 expression by shRNA (short hairpin
RNA) synthesis led to premature senescence of untrans-
formed human fibroblasts, whose features include G1
arrest, p21 induction, senescence-associated hetero-
chromatic foci (SAHF), and -gal staining. Importantly,
p400shRNA-induced premature senescence phenotypes
were rescued by coexpression of p53-shRNA or p21-
shRNA. Furthermore, p400 complex colocalized with
p53 on the p21 promoter. These data suggest that the
p400 complex inhibits p53 → p21 transcription and the
development of premature senescence.
Supplemental material is available at http://www.genesdev.org.
Received June 22, 2004; revised version accepted November
19, 2004.
The N-terminal region of adenoviral E1A interacts with
p400, a member of the SWI2/SNF2 chromatin remodel-
ing family (Fuchs et al. 2001). E1A mutants defective in
interacting with p400 cannot transform primary cells ef-
ficiently when coexpressed with activated Ras (Deleu et
al. 2001; Fuchs et al. 2001; Seger et al. 2002), suggesting
that p400/E1A complexes participate in the transforma-
tion process. p400 interacts with SV40 large T antigen
(Lill et al. 1997b), c-Myc (Fuchs et al. 2001), and the
tumor suppressor, p53 (Lill et al. 1997a). It is also a com-
ponent of the human TIP60/NuA4 complex (Ikura et al.
2000; Fuchs et al. 2001; Cai et al. 2003; Doyon et al.
2004), which has specific histone H4/H2A acetyltrans-
ferase activity (Ikura et al. 2000; Doyon et al. 2004).
ChIP (chromatin immunoprecipitation) analysis has
detected p400 complexes at certain c-Myc and E2F-regu-
lated promoters (Frank et al. 2003; Taubert et al. 2004).
Their recruitment to such promoters correlated with an
increase in histone acetylation in the surrounding chro-
matin and induction of transcription. These findings
suggest that p400-containing complexes exert key chro-
matin-remodeling functions and participate in transcrip-
tion regulation.
In the present study, retroviral-mediated shRNA was
used to target p400 complexes and to investigate the
outcomes of this perturbation in human cells. Specifi-
cally, acute depletion of p400 induced premature senes-
cence in multiple, untransformed human fibroblasts.
p400 shRNA-induced SAHF and other premature senes-
cence phenotypes were rescued by coexpression of shRNA
for p53 or p21, but not pRb. p400-depleted cells revealed
elevated p21 mRNA and protein expression. In keeping
with these findings, p400 was detected at or near the
p53-binding site in the p21 promoter. These data suggest
that p400 complexes inhibit p53 → p21 expression, and
that deregulated p21 expression leads to senescence.
Results and Discussion
p400-shRNAs cause cell cycle arrest, SAHF,
and premature senescence in untransformed
human fibroblasts
Multiple retroviral vectors each encoding an shRNA di-
rected against human p400 were constructed. The pro-
gram for antibiotic selection and analysis of cells ex-
pressing these vectors is shown in Figure 1A. When
IMR90 primary human diploid fibroblasts were trans-
duced with shRNA-p400#2 or shRNA-p400#4, endog-
enous p400 protein expression was suppressed (Fig. 1B,
cf. lanes 2,4 and 1). Moreover, shRNA-p400#2 and
ShRNA-p400#4 effectively suppressed p400 expression
in HeLa, T98G, telomerase-immortalized BJ fibroblasts
(BJ-tert), U2OS, and a primary human lung fibroblast
strain (Supplementary Fig. 7; data not shown). ShRNA-
p400#3 did not significantly affect the p400 protein level
(Fig. 1B) and was used as a negative control (Fig. 1D).
Suppression of p400 expression was associated with G1
arrest (Fig. 1D, graph i), decreased BrdU incorporation
(Fig. 1D, graph ii), and it inhibited proliferation of IMR90
(Fig. 1C). Similar results were observed in BJ-tert (data
not shown). None of these effects was detected when
experiments were performed on two transformed human
cell lines in which p53 function is compromised, includ-
ing HeLa and T98G (Supplementary Fig. 2).
Unlike naive IMR90, p400 shRNA-treated IMR90 be-
came elongated and spindle shaped. When their DNA-
staining properties were examined by fluorescence mi-
croscopy, ∼40%–60% of the culture revealed clustered
DAPI-dense regions (Fig. 2A, panel 3). These structures
were virtually absent in control cells (Fig. 2A, panel 1)
and are decidedly unusual in human tissue culture cells
in general. Spots of this type were recently described in
IMR90 undergoing replicative senescence or experienc-
ing activated Ras expression (Narita et al. 2003). They
were referred to as senescence-associated heterochro-
matic foci (SAHF) (Narita et al. 2003). SAHF were also
observed following p400 depletion in normal diploid
lung fibroblasts and in telomerase-immortalized BJ fibro-
blasts (data not shown). In contrast, T98G and HeLa cells
failed to display SAHF before or after p400 knockdown
(Supplementary Fig. 2; data not shown). Where tested,
the above-noted, DAPI-dense regions costained with an
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antibody to methylated histone H3 Lys 9 (Fig. 2A, panel
4), consistent with earlier findings (Narita et al. 2003).
The development of a SAHF phenotype following
p400 depletion led to a further analysis of whether p400
shRNA-treated cells, like their activated Ras-producing
counterparts, enter premature senescence. Indeed, p400
shRNA-treated IMR90 (Fig. 2B) displayed senescent -gal
staining, again suggesting that they were senescent. Two
independent shRNAs designed against two, different se-
quences of p400 suppressed p400 protein expression and
cell cycle progression (Fig. 1D). Each also induced SAHF
(Fig. 2A, panel 3 for shRNA-p400#4; data not shown) and
senescent -gal staining (Fig. 2B), linking this phenotype
to the specific targeting of p400.
To determine whether knockdown of other compo-
nents of the p400 complex lead to similar phenotypes,
shRNAs were designed against TIP48 and TIP49, two
subunits of this complex (Fuchs et al. 2001). Depletion of
TIP48 or TIP49 expression by shRNA recapitulated the
phenotypes of shRNA-p400 in IMR90 and BJ-tert, includ-
ing G1 arrest, decreased BrdU incorporation, and the de-
velopment of SAHF (Supplementary Fig. 1). Taken to-
gether, these data imply that acute loss-of-function of
the p400 complex is associated with premature senes-
cence.
Thus far, we have not detected a spontaneous decrease
of expression of the p400 complex in cells undergoing
replicative senescence (data not shown). If a perturbation
of p400-complex function is required for this outcome, it
must involve other molecular alteration(s) than simple
protein depletion.
shp400-infected IMR90 has elevated p21 expression
Since oncogenic Ras overexpression and p400 depletion
both induced premature senescence and SAHF (Serrano
et al. 1997; Narita et al. 2003), we compared the molecu-
lar features of these two states in search of similarities
and differences. Both perturbations led to maximum se-
nescent -gal staining at approximately day 10 post-in-
fection. Activated Ras overexpression had no effect on
p400 protein level, and shRNA-p400 transduction did
not activate endogenous Ras expression (Fig. 2C). More-
over, in Ras-expressing cells, there was up-regulation of
p16 (Fig. 2C), and some enhancement of p53 Ser15 phos-
phorylation (Fig. 2C), consistent with previous reports
(Serrano et al. 1997; Ferbeyre et al. 2000; Narita et al.
2003). However, shRNA-p400 did not affect the p16 pro-
tein level or p53 Ser15 phosphorylation, but was associ-
ated with p21 up-regulation (Figs. 2C, 3B). By quantita-
tive RT–PCR, significant increases in the p21 mRNA
level were reproducibly detected in shRNA-p400-treated
cells (Fig. 2D), suggesting an enhancement of p21 tran-
scription.
In keeping with its function as a cdk inhibitor (Sherr
and Roberts 1999), p21 (also known as sdi [senescent
cell-derived inhibitor]) is highly expressed in senescent
cells and inhibits DNA synthesis (Noda et al. 1994). In-
deed, it can elicit this phenotype on its own, for overex-
pression of p21 can result in premature senescence (Mc-
Connell et al. 1998) and SAHF (M. Narita and S.W. Lowe,
unpubl.). Moreover, it serves as a lifespan regulator, be-
cause knocking out p21 can extend the lifespan of hu-
man fibroblasts (Brown et al. 1997).
Figure 1. shRNA-p400-mediated cell cycle arrest in IMR90. (A)
Experimental design and time frame. (B) Immunoblot of p400 from
IMR90. (Super) The empty retroviral backbone control. Total pro-
tein loaded was standardized by Bradford assay (Bio-Rad). (C) Cell
growth assay performed in IMR90. (D) FACS analysis and BrdU in-
corporation assay from two independent experiments.
Figure 2. shRNA-p400 induces SAHF and premature senescence in
IMR90. (A) DNA staining by DAPI (panels 1,3) and H3K9-Me stain-
ing (panels 2,4) of cells as indicated. The cells in panels 2 and 4
correspond to the cells in panels 1 and 3, respectively. (B) Senescent
-gal staining of IMR90 following the indicated perturbations. Ras
was included as a positive control, and shRNA-c-myc and pSuper
were included as negative controls. (C) IB and IP-IB of the indicated
proteins from IMR90 exposed to the indicated perturbations. (D)
Quantitative RT–PCR measuring p21 mRNA in control IMR90 or
IMR90 exposed to shRNA against p400. Unnormalized actin and
p21 mRNA levels are presented in graph i. (Graph ii) After normal-
ization against actin mRNA, the relative p21 mRNA abundance was
calculated. The data presented are average values obtained from
quadruplicate samples.
p400 participates in the p53/p21 senescence pathway
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Inactivation of p53/p21, but not pRb, rescues p400
shRNA-induced premature senescence in IMR90
Ras-induced SAHF can be partially rescued by suppress-
ing the pRb/E2F pathway (Narita et al. 2003), while in-
activation of p53 had no such effect (Narita et al. 2003).
In light of these findings, we asked whether the pRb or
p53 pathways contribute to shRNA p400-induced pre-
mature senescence. Consistent with a previous report
(Narita et al. 2003) and as a positive control, it was pos-
sible to use shRNA-pRb to partially rescue Ras-induced
SAHF (data not shown). However, shRNA-pRb had no
effect on shRNA-p400-induced SAHF, cell cycle arrest,
or senescent -gal staining (Fig. 3A, Exp1; Supplemen-
tary Fig. 3). Its knockdown of pRb expression is shown in
Supplementary Figure 4A. Furthermore, overexpression
of cyclin E or cdk4 (R24C) (Supplementary Fig. 4B), both
predicted to relieve pocket protein-mediated transcrip-
tion repression of certain E2F-activated genes (Rane et al.
2002), were also unable to rescue shRNA-p400-induced
SAHF and senescence -gal staining (Fig. 3A, Exp4;
Supplementary Fig. 3). In contrast, shRNA depletion of
p53 did rescue shRNA-p400-induced SAHF, cell cycle
arrest, and senescent -gal staining (Fig. 3A, Exp2 and
Exp4; Supplementary Figs. 3, 5). Importantly, expression
of shRNA-p53 did not reduce the efficiency with which
shRNA-p400 suppressed p400 expression in cells ex-
posed to a combination of shRNAs for p53 and for p400
(Fig. 3B). Furthermore, overexpression of a dominant-
negative p53 mutant (p53DD) partially suppressed
shRNA-p400-induced SAHF (Fig. 3A, Exp5). Taken to-
gether, the above-noted data imply that the SAHF and
senescence effects associated with p400 knockdown de-
pend upon the existence of normal p53, but not pRb,
function. This is the opposite of the mechanism driving
SAHF that arise after activated Ras expression (Narita et
al. 2003).
While p400 depletion led to p21 up-regulation, p53
depletion completely abolished basal p21 expression
(Fig. 3B). The latter effect is likely dominant, because the
p21 level remained undetectable in cells treated with
both shRNA-p53 and shRNA-p400 (Fig. 3B). One pos-
sible prediction from these and the above-noted results is
that p21 is the prime lifespan control protein at work in
the p400 pathway.
To test this, we asked whether p21 depletion also res-
cues cells from shRNA-p400-mediated premature senes-
cence. Down-regulation of p21 expression by shRNA-
p21 (Fig. 3C, top, cf. lanes 1 and 3, and lanes 2 and 4)
substantially reduced the incidence of shRNA-p400-in-
duced senescent phenotypes (Fig. 3A, Exp3). A large frac-
tion of cells treated with shRNA-p400 revealed SAHF
and strong p21 staining (for examples, cf. Supplementary
Fig. 6). Both SAHF and p21 staining were greatly reduced
in cells doubly treated with shRNA-p21 and shRNA-
p400 (Supplementary Fig. 6). Importantly, the shRNA
p21 reagent did not overtly compromise the ability of
shRNA p400 to suppress p400 expression in the cells
doubly infected with viruses encoding shRNAs for p21
and p400 (Fig. 3C, bottom). Overall, we conclude that the
p53–p21 pathway contributes to shRNA-p400-induced
premature senescence.
It is understandable that no phenotype was observed
when shRNA-p400 was introduced into HeLa and T98G
cells (Supplementary Fig. 2), since p53 function in these
cells is compromised by the presence of HPV E6 and of a
genomic loss of function mutation, respectively (Hall et
al. 1998; Goodwin and DiMaio 2001). To further test the
above-noted hypothesis, shRNA-p400 was transduced
into U2OS cells, an osteosarcoma cell line carrying wild-
type p53 alleles. In p400-depleted U2OS cells, increased
p21 expression and G1-arrested cells were observed
(Supplementary Fig. 7A,B). Consistent with the observa-
tion in IMR90 (Fig. 2C), p400 depletion in U2OS cells did
not affect the p53 expression level (Supplementary Fig.
7C). Unlike IMR90, however, SAHF were not observed
in U2OS following p400 depletion, or exogenous p21
overexpression (data not shown). Therefore, elevated ex-
pression of p21 is not sufficient to cause SAHF or pre-
mature senescence in U2OS. This notwithstanding, p21
overexpression or p400 depletion were not inert events
in these cells, since both led to marked inhibition of
DNA synthesis (Supplementary Fig. 7D).
p400 complexes colocalize with p53
on the p21 promoter
p21 expression is normally up-regulated by p53. One out-
come is G1 arrest (el-Deiry et al. 1993; Macleod et al.
1995; Vogelstein et al. 2000). Given
that p400 depletion induces p21 syn-
thesis, one wonders whether p400
plays a direct role in down-regulating
p53-dependent transcription of p21. In
this regard, using ChIP analysis, we de-
tected p400 bound to a region that
overlaps the distal p53-binding site
within the p21 promoter (Fig. 4B, #1, cf.
lanes 8 and 3,7). Consistently, TIP49, a
p400 complex member (Fuchs et al.
2001), was also detected in the same
region (Fig. 4C). p400 binding at this
site was specific, since no p400 was de-
tected at the proximal TGF response
element-containing region within the
p21 promoter (Fig. 4B, #2), nor was it
bound to a region ∼3 kbp downstream
of the p21 transcription initiation site
(Fig. 4B, #3).
By performing ChIP with an anti-
Figure 3. Inactivation of p53/p21, but not pocket family proteins, rescues shRNA-p400-
mediated premature senescence. (A) Summary of SAHF and senescent -gal staining in
IMR90 exposed to the indicated perturbations. (B,C) IB and IP-IB of the indicated IMR90
proteins after the indicated perturbations.
Chan et al.
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p400 Ab and then reimmunoprecipitating with anti-p53
Ab (DO-1), a PCR-amplified signal was detected from the
distal p53-binding region (Fig. 4D, #1), but not from the
region 3 kbp downstream of the transcription initiation
site (Fig. 4D, #3). Therefore, both p53 and p400 were
colocated within the distal p53-binding/regulatory re-
gion of the p21 promoter. These data are consistent with
a model in which interplay between p53 and p400 con-
tributes to normal regulation of the p21 promoter. While
p53 exerts a positive effect on this element, p400 appears
to exert a negative one. As a result, depletion of p400
elicited p53-dependent transcription of the p21 gene, and
elevated p21 expression can lead to premature senes-
cence (McConnell et al. 1998).
By quantitative ChIP analysis, multiple experiments
demonstrated 60%–70% more p53 bound to site #1 in
IMR90 cells depleted of p400, compared with control
IMR90-pSuper cells (Fig. 4E). This phenomenon is spe-
cific to the p21 promoter, since there was no increase in
p53 binding to the puma or bax promoters in the same
experiments (data not shown). Furthermore, no p400 was
detected at the p53-binding region of the puma or bax
promoters (data not shown). Thus, it is possible that in-
creased p53 binding to the p21 promoter in p400-de-
pleted IMR90 contributed to the enhanced p21 expres-
sion observed.
In conclusion, p400, an SWI2/SNF2 chromatin-remod-
eling factor, plays a role in regulating p53 → p21 tran-
scription and eliciting a cellular senescence program.
Acute depletion of p400 or components of the p400 core
complex in primary cells led to G1 arrest, SAHF, induc-
tion of p21, and senescence -gal staining, all features
indicative of cells entering senescence (Narita et al.
2003). By epistatic analysis, p400 shRNA-mediated se-
nescence has been linked to the p53/p21 pathway, but
not the pRb pathway. This is the opposite of the mecha-
nism leading to Ras-induced SAHF (Narita et al. 2003).
These findings elicit speculation that p21 and p16 par-
ticipate in distinct senescence pathways that respond to
different cues (Fig. 5; Herbig et al. 2004).
Cellular senescence has been hypothesized to serve as
a barrier against tumor development. The ability to over-
come senescence is a prerequisite for tumor formation
(Sager 1991; Hanahan and Weinberg 2000). We have ob-
served that both E1A and c-Myc up-regulate p400 expres-
sion (data not shown). Furthermore, p400 is required for
E1A-dependent apoptosis (A. Samuelson, M. Narita, and
S.W. Lowe, unpubl.). Given the results reported above,
one wonders whether E1A or c-Myc, by up-regulating
p400 expression, override p53/p21-dependent cell cycle
arrest, an outcome that was suggested to sensitize cells
to p53-dependent apoptosis (Seoane et al. 2002). If so, one
would argue that c-Myc and/or E1A do not inactivate
p400. Rather, one wonders whether c-Myc/p400 or E1A/
p400 complexes exhibit a qualitative alteration in p400
function or even its activation. Since senescence is sus-
pected of serving as a major component of tumor sup-
pression and is associated, in at least one setting, with
suppression of p400 complex function, it is conceivable
that up-regulation of p400 expression/function by cer-
tain oncogenes (and, quite possibly, its binding to the
N-terminal region of E1A [Fuchs et al. 2001]) contributes
to neoplastic transformation. An analysis of whether
p400 function is deregulated in certain human tumors
now seems timely.
Materials and methods
Cell culture, cell cycle analysis, and plasmids
All cells were cultivated at 37°C in a 10% CO2-containing atmosphere;
293T, IMR90, HeLa, U2Os, and T98G were maintained in DMEM
Figure 4. p400 colocalizes with p53 on the p21 promoter. (A) Dia-
grammatic presentation of the p21 promoter, indicating the primers
used for ChIP (#1, #2, and #3). (B–D) ChIP analysis of p400 com-
plexes bound at the p21 promoter using the indicated primer sets.
Antibodies used for ChIP are indicated. Minus sign (−) indicates a
control reaction mixture with no Ab added. p53 and max bound to
regions #1 and #2, respectively, were as reported (Kaeser and Iggo
2002; Seoane et al. 2002; Wu et al. 2003). The presence of p53 in #2
could be consistent with the report of a second p53-binding site ∼1
kbp upstream of the transcription start site in the p21 promoter
(Resnick-Silverman et al. 1998). The arrows indicate the specific
PCR products, and the asterisk indicates the position of a primer
dimmer band. (E) Quantitative analysis of p53 binding to the p21
promoter in control IMR90 and IMR90 depleted of p400. Results
from three different ChIP experiments are presented. In each ChIP
experiment, triplicate samples were subjected to quantitative PCR,
and the average value was used to calculate percent of total input
chromatin bound. In three experiments, there were, respectively,
1.69, 1.60, and 1.64 times more p53 binding to #1 in IMR90-shRNA-
p400 cells compared with control cells.
Figure 5. A model of p400 regulation of p53 → p21 expression and
its related senescence program. p400–p53/p21 and Ras–p16/pRb are
two distinct pathways leading to SAHF. p400 represses p53 → p21
transcription to prevent premature senescence. It remains to be de-
termined whether p400 complex function is perturbed in replicative
senescence, and if so, whether its perturbation contributes to the
biological outcome.
p400 participates in the p53/p21 senescence pathway
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supplemented with 10% FBS and antibiotics. BJ-Tert cells were cultured
in 4:1 DMEM/medium 199 (Invitrogen), supplemented with 15% FBS
and antibiotics. Retroviral production and infection protocols were as
described (Serrano et al. 1997; Narita et al. 2003). When cells were doubly
infected by viruses, cells were first selected with Puromycin (2 µg/mL)
for 2 d, followed by Hygromycin (75 µg/mL) for 2 d. Routinely, 60%–80%
of the cells survived selection. The cell growth assay and senescence
-gal-staining protocol have been described (Serrano et al. 1997; Narita et
al. 2003). For FACS and BrdU incorporation assays, 4 × 105 cells were
seeded on 10-cm plates 30–36 h before harvesting. Ten micromolar of
BrdU was added to the culture medium for 45 min before harvesting.
BrdU-free cells (and stained with -BrdU Ab) were included as negative
controls. The following virus combinations were used in the experiment
presented in Figure 3, Exp1 [pSuper-shRNA-Rb(Hygro) + pSuper-shRNA-
p400#3(Puro); pSuper-shRNA-Rb(Hygro) + pSuper-shRNA-p400#4(Puro);
pSuper(Hygro) + pSuper-shRNA-p400#3; pSuper(Hygro) + pSuper-shRNA-
p400#4(Puro)]. In Exp2, [pSuper-shRNA-p400#4(Hygro) + pSuper(Puro);
pSuper-shRNA-p400#4(Hygro) + pSuper-shRNA-p53(Puro); pSuper(Hygro)
+ pSuper(Puro); pSuper(Hygro) + pSuper-shRNA-p53(Puro)]. In Exp3, [pSuper
(Puro) + pSuper-shRNA-p400#4(Hygro); pSuper-shRNA-p21(Puro) + pSuper-
shRNA-p400#4(Hygro) and pSuper-shRNA-p21(Puro) + pSuper(Hygro)]. In
Exp5, [pSuper(Puro) + pBabe(neo); pSuper-shRNA-p400(Puro) + pBabe(neo);
pSuper(Puro) + pBabe-p53DD(neo); pSuper-shRNA-p400(Puro) + pBabe-
p53DD(neo)]. pBabe (Puro)–cyclin E, pBabe (Puro)–cdk4 (R24C) and pBabe
(Puro)–RasV12 have been described (Serrano et al. 1997). pBabe-p53DD
(Shaulian et al. 1992) was a kind gift of Dr. W. Hahn (Dana-Farber Cancer
Institute, Boston, MA). shRNAs against p53 and pRb were described in
Voorhoeve and Agami (2003). shRNAs against p400, and TIP49 were cloned
into pSuperRetro-(Puro) or pSuperRetro-(Hygro)-based vectors (Oligoen-
gine). Sequence information can be obtained upon request.
Immunofluorescence (IF)
Cells were fixed with 4% paraformaldehyde and subjected to DAPI stain-
ing. The IF procedure for anti-dimethyl H3K9 (Upstate Biotechnology)
and p21 (c-19, Santa Cruz) Ab was described previously (Ganesan et al.
2002).
Antibodies
Antibodies against c-myc (N262), max (c-17), pRb (c-15), and p21 (c-19),
were from Santa Cruz Biotechnology. Antibody against -tubulin (T5168)
was from Sigma. Antibody against pRb (G3-245) and the BrdU-staining
kit were from Pharmingen. Antibodies against p16 (05-418) and anti-
H3K9Me were from Upstate Biotechnology. p53 Ab (DO-1) was from
Calibiochem. p53 Ser15 Ab and anti-p21 (DCS60) were from Signal
Transduction Lab. Antibodies against TIP49 and TIP48 were raised as
rabbit polyclonal sera against GST-TIP49 (full-length) and His-TIP48
(full-length), respectively. Antibodies against p400 (H97) and (H50)
were raised against GST-p400 (1-300) and an N-terminal p400 peptide
(SEGEEQPAHPNPPPS), respectively. Anti-p400 (RW144) was described
(Fuchs et al. 2001). All polyclonal Abs were affinity purified.
Immunoprecipitation (IP) and ChIP
IP were performed by a slight modification of a prior protocol (Fuchs et al.
2001). Specifically, cell extract was collected in NETN buffer (50 mM
Tris-HCl at pH 8.0, 150mM NaCl, 0.1% NP-40 and protease inhibitor
cocktail [Roche]), supplemented with 0.5% Triton. ChIP and IP-reIP
ChIP were performed as described previously (Shang et al. 2000). Primers
used in the ChIP assays were described (Kaeser and Iggo 2002; Wu et al.
2003). For quantitative ChIP analysis on the distal p53-binding site in the
p21 promoter, the primers CCCTTCCTCACCTGAAAACA and GTG
GCTCTGATTGGCTTTCTG were used. This set of primers did not
yield primer dimers in PCR reactions. The method for quantitating the
results of ChIP experiments has been described (Frank et al. 2001).
Quantitative RT–PCR
Total cellular RNA was harvested by RNeasy (QIAGEN). First-strand
cDNA synthesis was carried out using the Superscript first-strand syn-
thesis system (Invitrogen). Quadruplicate samples were subjected to
quantitative PCR using iCycler (Bio-Rad), and the primers were described
(Kaeser and Iggo 2002). PCR for actin mRNA was used as an internal
control. The relative abundance of p21 mRNA was calculated after nor-
malization using actin mRNA.
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